\
&
Contact us
\
&
Contact us
Starts in 3 hours from now
LocationLisbon
The MedTech Forum is a conference focusing on health and medical technology industry in Europe, organised since 2007. Join industry leaders, innovators and investors to discuss the future opportunities in the medical technology sector.
The 2025 programme will feature leading voices in the medical technology community, including industry experts and key stakeholders. With the event, the organiser wants to contribute to tackling the ever- evolving opportunities and challenges for the MedTech industry, from innovation and digital transformation to regulatory developments and sustainability.
The event feastures speakers from the European Commission and the Innovative Health Initiative (IHI).
More information, the detailed agenda and registration on the event webpage. Please be aware this is a paying event. Please make sure to check the ticket price for your stakeholder category before registry.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
